Team:Amsterdam/practices/overview

From 2012.igem.org

(Difference between revisions)
(Created page with "{{Team:Amsterdam/stylesheet}} {{Team:Amsterdam/scripts}} {{Team:Amsterdam/Header}} {{Team:Amsterdam/Sidebar1}} <div id="content-area"> <div id="sub-menu" class="content-block"> ...")
Line 6: Line 6:
<div id="content-area">
<div id="content-area">
<div id="sub-menu" class="content-block">
<div id="sub-menu" class="content-block">
-
 
+
<h1>Human Practices: Overview</h1>
Synthetic biology (SB) is a quickly developing branch of biotechnology with many promising benefits for human society. As a consequence of this development, awareness among the public increases. Past debates on genetic engineering suggest that in order to omit exaggerated hopes and fears, scientists should adopt an open approach towards the public. The whole concept of involving the public has only been around for the past three decades; it was in the early 1980s that scientists and policy makers began to acknowledge that public engagement could be beneficial to both science and society. This is particularly the case with developments in the field of biotechnology because they come with both high expectations for society as well as concerns about risks, privacy, sustainability and commercialization. Also, involvement of relevant stakeholders is required to enable a flexible way to deal with upcoming problems. This approach, which is known by Constructive Technology Assessment (CTA)[link], claims to effectuate a smooth incorporation of the societal context into the development process of SB in general. (and our project in specific.)
Synthetic biology (SB) is a quickly developing branch of biotechnology with many promising benefits for human society. As a consequence of this development, awareness among the public increases. Past debates on genetic engineering suggest that in order to omit exaggerated hopes and fears, scientists should adopt an open approach towards the public. The whole concept of involving the public has only been around for the past three decades; it was in the early 1980s that scientists and policy makers began to acknowledge that public engagement could be beneficial to both science and society. This is particularly the case with developments in the field of biotechnology because they come with both high expectations for society as well as concerns about risks, privacy, sustainability and commercialization. Also, involvement of relevant stakeholders is required to enable a flexible way to deal with upcoming problems. This approach, which is known by Constructive Technology Assessment (CTA)[link], claims to effectuate a smooth incorporation of the societal context into the development process of SB in general. (and our project in specific.)
Line 13: Line 13:
This approach, what we call:….., is further explained in the method section. Curious on how we applied this approach to the Cellular Logbook? Check the results section. In Conclusion, you can see how we benefitted from this approach.
This approach, what we call:….., is further explained in the method section. Curious on how we applied this approach to the Cellular Logbook? Check the results section. In Conclusion, you can see how we benefitted from this approach.
-
Quote:
+
<blockquote style="background-color: lightgrey; border: solid thin grey;">
-
(Weldon, 2004): “Modern science & technology takes place against a wider background of social values and ethical judgments”  
+
(Weldon, 2004): “Modern science & technology takes place against a wider background of social values and ethical judgments”
“It is important to address ethical and safety concerns, and to address potential or perceived risks of synthetic biology from the very beginning, so that future development work can be done in conditions of public trust.“
“It is important to address ethical and safety concerns, and to address potential or perceived risks of synthetic biology from the very beginning, so that future development work can be done in conditions of public trust.“
-
 
+
</blockquote>
</div>
</div>

Revision as of 10:09, 26 September 2012

Human Practices: Overview

Synthetic biology (SB) is a quickly developing branch of biotechnology with many promising benefits for human society. As a consequence of this development, awareness among the public increases. Past debates on genetic engineering suggest that in order to omit exaggerated hopes and fears, scientists should adopt an open approach towards the public. The whole concept of involving the public has only been around for the past three decades; it was in the early 1980s that scientists and policy makers began to acknowledge that public engagement could be beneficial to both science and society. This is particularly the case with developments in the field of biotechnology because they come with both high expectations for society as well as concerns about risks, privacy, sustainability and commercialization. Also, involvement of relevant stakeholders is required to enable a flexible way to deal with upcoming problems. This approach, which is known by Constructive Technology Assessment (CTA)[link], claims to effectuate a smooth incorporation of the societal context into the development process of SB in general. (and our project in specific.)

Based on this theory, the Amsterdam iGEM team 2012 designed a new approach in human practices (flow-diagram), which can be adopted by each future iGEM team. In practice, this approach embraces the involvement of experts from various relevant disciplines to share their knowledge and opinions on the technical, safety, ethical, social and legal issues regarding an iGEM project.

This approach, what we call:….., is further explained in the method section. Curious on how we applied this approach to the Cellular Logbook? Check the results section. In Conclusion, you can see how we benefitted from this approach.

(Weldon, 2004): “Modern science & technology takes place against a wider background of social values and ethical judgments” “It is important to address ethical and safety concerns, and to address potential or perceived risks of synthetic biology from the very beginning, so that future development work can be done in conditions of public trust.“

Retrieved from "http://2012.igem.org/Team:Amsterdam/practices/overview"